What top creators are saying about Spruce Biosciences(SPRB)

The bullish but catalyst-dependent view centered on an anticipated BLA filing for an enzyme replacement therapy for Sanfilippo syndrome, possible FDA approval, and commercial launch; regulatory and uptake risks remain.

The investment case depends on BLA submission, FDA approval, and early sales. The speaker saw significant upside potential but cautioned that approval and a successful launch are uncertain and the stock had been weak.

The speaker says he is very bullish on Spruce and likes the mentioned ticker 'SPRV,' but the company identification and ticker are uncertain and the thesis is not explained.

The speaker was bullish on the company's prospects for regulatory approval and a high-priced enzyme replacement therapy, while noting risks around approval, reimbursement, patient identification, and commercial launch.

The speaker said he liked Spruce, called it a good discount, and described himself as very bullish.

Shkreli said he believes the drug works and expected a BLA submission, while noting that approval, a successful launch, and sales in a very small patient population remain uncertain.

Potential upside is tied to BLA submission, FDA review, and commercial execution; the small patient population and uncertain milestones make this high risk.

Maintains a long-term bullish stance with fundamental potential to reach $500 over an extended time horizon as a high-volatility clinical play.

Maintains a strongly bullish outlook with confidence in achieving FDA approval for key pipeline treatments.

Long position following a catalyst event, with high confidence in substantial remaining upside that is not strictly dependent on a single binary outcome.

Pipeline progress is not yet reflected in valuation; holds high long-term conviction with projected 5x to 10x upside potential.

Remaining long despite the trade performing poorly thus far.

Highlighted as a strategic focus in the biotech sector for rare disease drugs.

Maintains a bullish stance despite market fluctuations, citing massive upside potential.

Described as a '10x' opportunity and 'no-brainer'; potential for a $100M Priority Review Voucher (PRV) sale.

The speaker is 'over the moon about' this stock and confirms they are 'still long', indicating a strong bullish conviction.

The host gave a direct buy recommendation, stating 'I think it's still a buy. Spruce is still a buy.'

The speaker is very confident in long-term potential, believing it could be a $1,000 stock. The main risk is initial FDA approval, but ultimate approval is expected. A price below $100 is seen as a buying opportunity.